BSG and malaria: Previous studies have shown that antibodies to Rh5 (Chiu et al., 2014; Douglas et al., 2014) or basigin (Reddy et al., 2014) block the entry of the malaria parasite into the erythrocyte, and therefore Rh5 is a promising vaccine target and potentially a small molecule therapeutic target.